Oncotide Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery and development of drugs that modulate protein phosphatases, which fundamentally disrupt cancer cells' ability to proliferate and survive. The company's development portfolio focuses on inhibition of the SET oncoprotein, a potent inhibitor of protein phosphatase 2A that deactivates proteins, which stimulate uncontrolled growth of cancer cells, as well as aid in evasion of regulated cell death. Its platform also focuses on other therapeutics areas, including autoimmune, inflammatory, and wound-healing diseases.
